Τόμος 39 (2021) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 39 (2021) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek
Τίτλος – Title

Η Εμπλοκή του Παράγοντα Ενεργοποίησης Αιμοπεταλίων (PAF) σε διάφορες Ασθένειες

Involvement of Platelet Activating Factor (PAF) in various Diseases
Συγγραφέας – Author

Maria Trapali

Laboratory of chemistry, biochemistry and cosmetic science, Department of Biomedical Science, University of West Attica, Agiou Spyridonos 28, Egaleo, Attiki, Greece
Παραπομπή – Citation

M. Trapali. Involvement of Platelet Activating Factor (PAF) in various Diseases. Epitheorese Klin. Farmakol. Farmakokinet. 2021, 39, 1, 29-34.

Ημερομηνία αναδημοσίευσης – Republication Date
14-03-2021
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά- English
Λέξεις κλειδιά – Keywords

Activating Factor, Inflammation, CNS, Cancer, Diabetes Mellitus
Λοιποί Όροι – Other Terms

Μελέτη
Article
Περίληψη – Summary

Platelet Activating Factor (PAF) is a lipid compound, glyceryl ether analog of phosphatidylcholine. PAF through its binding to a well-characterized receptor initiates a multitude of cellular pro-inflammatory actions that are thus involved in the pathology of most chronic diseases, including cardiovascular and renal diseases, central nervous system (CNS) diseases and cancer. It has also played a role in several other chronic inflammation-related diseases, such as type I and type II diabetes, acute pancreatitis, liver damage, inflammatory eye diseases, vascular dysfunction during acute lung injury and autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and Crohn’s disease.
Αναφορές – References
  1. Demopoulos CA, Pinckard RN, Hanahan DJ (1979), Platelet-activating Evidence for1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators, Journal of Biological Chemistry254(19),9355-8.
  2. Shindou , Nakanishi H.,Harayama T.,Taguchi S.,ShimizuT.(2007) A Single Enzyme Catalyzes Both Platelet-activating FactorProduction and Membrane Biogenesis of Inflammatory Cells: Cloning and Characterization of ACETYL-CoA: LYSO-PAFACETYLTRANSFERASE,JBC 282(9),6532-6539. https://www.sciencedirect.com/science/articl e/pii/S0021925820522631#!
  3. Tselepis D., Chapman M.J. (2002) Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl.3, 57–68.
  4. Rosenson S., Stafforini D.M. (2012) Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res.,53,1767– 1782
  5. Bochkov V., Gesslbauer B., Mauerhofer C., Philippova , Erne P., Oskolkova O.V. (2017) Pleiotropic effects of oxidizedphospholipids. Free Radic. Biol. Med.111, 6– 24.
  6. Bochkov V.N., Oskolkova O.V., Birukov K.G., Levonen A.-L., Binder C.J., Stöckl J. (2010) Generation and biological activities ofoxidized Antioxid. Redox Signal. 12,1009–1059.
  7. Bochkov V.N. (2007) Inflammatory profile of oxidized Thromb. Haemost. 97,348.
  8. Fu , Birukov K.G. (2009) Oxidized phospholipids in control of inflammation and endothelial barrier. Transl. Res.153, 166– 176.
  9. Spinas E., Kritas S.K., Saggini A., Mobili A., Caraffa A., Antinolfi P., Pantalone A., Tei M., Speziali A., Saggini R. (2014) Role of mast cells in atherosclerosis: A classical inflammatory disease. J. Immunopathol. Pharmacol.27,517–521.
  10. Brailoiu , Barlow C.L., Ramirez S.H., Abood M.E., Brailoiu G.C. (2018) Effects of platelet-activating factor on brainmicrovascular endothelial         cells. Neuroscience 377,105–113.
  11. Bellizzi J., Geathers J.S., Allan K.C., Gelbard H.A. (2016) Platelet-activating factor receptors mediate excitatory postsynaptichippocampal injury in experimental autoimmune encephalomyelitis. J. Neurosci.36,1336–1346
  12. Briones M.R.S., Snyder A.M., Ferreira R.C., Neely E.B., Connor J.R., Broach J.R. (2018) A possible role for platelet-activating factor receptor in amyotrophic lateral sclerosis Front.Neurol.9, https://doi.org/10.3389/fneur.2018.00039
  13. Camussi G. (1986) Potential role of platelet- activating factor in renal Kidney Int. 29,469–477
  14. Fragopoulou E., Iatrou C., Demopoulos C.A. (2005) Characterization of acetyl-Coa: Lyso- paf acetyltransferase of humanmesangial Mediat. Inflamm. 263–272
  15. Plante E., Hebert R.L., Lamoureux C., Braquet P., Sirois P. (1986) Hemodynamic effects of paf-acether. Pharm. Res.Commun. 18,173–179
  16. Melnikova O., Villares G.J., Bar-Eli M. (2008) Emerging roles of PAR-1 and PAFR in melanoma metastasis. CancerMicroenviron.1,103–111.
  17. Melnikova O., Bar-Eli M. (2009) Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 22,257–267
  18. Sahu R.P., Harrison K.A., Weyerbacher J., Murphy C., Konger R.L., Garrett J.E., Chin-Sinex H.J., Johnston M.E., DynlachtJ.R., Mendonca M. (2016) Radiation therapy generates platelet-activating factor agonists. Oncotarget. 7,20788–20800.
  19. Da Silva-Jr , Chammas R., Lepique A., Jancar S. (2017) Platelet-activating factor (PAF) receptor as a promising target forcancer cell repopulation after radiotherapy. Oncogenesis. 6, e296.
  20. Denizot Y, Chianéa T, Labrousse F, Truffinet V, Delage M, Mathonnet M. (2005) Platelet- activating factor and human thyroid cancer. Eur J Endocrinol. 153(1),31–40
  21. Denizot Y, Desplat V, Drouet M, Bertin F, Melloni B. (2001) Is there a role of platelet- activating factor in human lung cancer? Lung 33(2),195–202
  22. Hackler PC, Reuss S, Konger RL, Travers JB, Sahu (2014) Systemic platelet- activating factor receptor activationaugments experimental lung tumor growth and metastasis. Cancer Growth Metastasis. 7, S14501.
  23. Palgan , Bartuzi Z. (2015) Platelet activating factor in allergies. Int. J. Immunopathol. Pharmacol. 28,584–589.
  24. Farbman , Michelson K. (2016) Anaphylaxis in Children Curr Opin Pediatr. 28(3), 294–297.
  25. Trapali M., Mavri-Vavayanni M., Siafaka A. (1996) PAF acetylhydrolase activity and PAF levels in pancreas and plasma of diabetic, fasted and well-fed rat. Life Sciences 59(10), 849-857
  26. Phenekos C, Siafaka A., Trapali M., Botitsi , Mavri M. (1992) Effect of gliclazide on PAF induced platelet aggregation in patients with non-insulin dependent Diabetes Mellitus metabolism. 41(5),30-32
  27. Ersoy B., Huseyinov A., Darcan (2005) The role of platelet-activating factor in pathogenesis of type 1 diabetes. Diabetes Care.28,980
  28. Kudolo G.B., DeFronzo R.A. (1999) Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus. Prostaglandins Another Lipid Mediat. 57,87–
  29. Liu R., Xia S.H. (2006) Role of platelet- activating factor in the pathogenesis of acute pancreatitis. World J. Gastroenterol.12,539– 545.
  30. Karidis N.P., Kouraklis G., Theocharis S.E. (2006) Platelet-activating factor in liver injury: A relational scope. World J. Gastroenterol. 12,3695–3706.
  31. Frost B.L., Caplan M.S. (2013) Necrotizing enterocolitis: Pathophysiology, platelet- activating factor, and Semin.Pediatr. Surg. 22,88–93
  32. Nitoda E., Moschos M.M., Mavragani C.P., Koutsilieris (2012) Ocular actions of platelet-activatingfactor: Clinical implications.Expert Opin. Ther. Targets. 16,1027–1039.
  33. Hikiji , Takato T., Shimizu T., Ishii S. (2008) The roles of prostanoids, leukotrienes, and platelet-activating factorin bonemetabolism and disease Progress in Lipid Research 47, 107–126
  34. Yin -J., Chen Z.-Y., Zhu X.-N., Hu J.-J. (2017) Loss of PAFR prevents neuroinflammation and brain dysfunction aftertraumatic brain injury. Sci. Rep. 7,40614.
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

Ετικέτες , , , , , , , , .Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.